You might also like
Theravance Biopharma, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative medicines that address unmet medical needs. The company focuses on creating treatments that improve the lives of patients, leveraging its expertise in pharmaceutical research and development. Its portfolio includes FDA-approved therapies and investigational drugs targeting chronic and rare conditions.
- YUPELRI® (revefenacin) - FDA-approved inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD), co-promoted with Viatris under a profit-sharing arrangement.
- Ampreloxetine - Late-stage investigational norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), currently in Phase 3 clinical trials.
- TRELEGY Royalties - Receives milestone payments and royalties from Royalty Pharma Investments based on global net sales of TRELEGY.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Rick E. Winningham ExecutiveBoard | Chief Executive Officer | Member of the Biotechnology Industry Organization's board of directors; Board member at Jazz Pharmaceuticals; Board member at Rivus Pharmaceuticals | Rick E. Winningham has served as Chief Executive Officer of TBPH since June 2014 and as Chairman of the Board since July 2013. Previously, he held senior roles at Innoviva and Bristol Myers Squibb, significantly contributing to the biopharmaceutical industry. | View Report → |
Áine Miller Executive | Senior Vice President, Development and Head of Ireland Office | Áine Miller is the Senior Vice President, Development and Head of Ireland Office at TBPH since November 7, 2023. She previously held executive roles in regulatory affairs and clinical safety at TBPH and has over 20 years of experience, including positions at Alkermes, Elan, and Allergan Medical. | ||
Aziz Sawaf Executive | Senior President and Chief Financial Officer (CFO) | Aziz Sawaf is the Senior President and Chief Financial Officer at Theravance Biopharma, Inc. since January 2023. Previously, he served as Vice President of Finance and was a member of the Senior Leadership Team from October 2021 to December 2022. | ||
Brett A. Grimaud Executive | Senior Vice President, General Counsel, and Secretary | Brett A. Grimaud has been serving as Senior Vice President, General Counsel, and Secretary at Theravance Biopharma since June 2022, after holding roles such as Vice President and General Counsel from October 2021 to June 2022. His extensive legal background includes previous positions in corporate counsel and securities law. | ||
Rhonda F. Farnum Executive | Chief Business Officer and Senior Vice President, Commercial and Medical Affairs | Rhonda F. Farnum is the Chief Business Officer and Senior Vice President, Commercial and Medical Affairs at TBPH since December 2021, and she previously served as Vice President, Sales and Marketing starting in July 2018. | ||
Anne Gray Board | Chair of the Board | Maravai LifeSciences (since November 2020) ; 4D Molecular Therapeutics (since July 2020) ; Morphic Therapeutic (since April 2021) | Susannah Gray (referred to as Anne Gray in the query) serves as Chair of the Board at TBPH, bringing over 30 years of biopharmaceutical expertise focused on corporate finance and capital markets. She was also appointed as an independent board member on February 27, 2023, and participates in key governance committees. | |
Dean J. Mitchell Board | director | Board Member at Precigen, Inc. (since March 2009); Board Member at Praxis Precision Medicines, Inc. (since August 2020) | Dean J. Mitchell has served as a director at Theravance Biopharma, Inc. since June 2014 and is a member of the Compensation Committee. He has extensive experience in the pharmaceutical industry, holding board roles at Precigen, Inc. since March 2009 and at Praxis Precision Medicines, Inc. since August 2020 among other executive and board positions. | |
Deepika R. Pakianathan Board | Director | Managing Member at Delphi Ventures since 2001 ; CEO of Redd Pharmaceuticals, Inc. since September 2019 ; CEO of another privately held discovery-stage biopharmaceutical company since August 2023 | Deepika R. Pakianathan, Ph.D., serves as a Director at Theravance Biopharma since July 2020 and has extensive experience in biotechnology, including roles such as a VP in the healthcare group at JP Morgan Chase and a postdoctoral scientist at Genentech. | |
Eran Broshy Board | Director | Board Member at Certara (since July 2022) ; Chairman at Thirty Madison ; Member of MIT Corporation ; Chairman of American Friends of the Open University of Israel ; Board Governor of American Jewish Committee | Eran Broshy has served as Director at Theravance Biopharma since June 2014. He also holds key committee roles including Audit Committee Member since April 2015 and Compensation Committee Member (and Chair since October 2014). | |
James Kelly Board | Director | Managing Director and Member of the Investment Committee at Weiss Asset Management | James Kelly serves as a Director at TBPH since April 2023 and is a member of the nominating/corporate governance committee since August 2023. Prior to his TBPH role, he has built a strong career as the Managing Director and a Member of the Investment Committee at Weiss Asset Management since November 2010, in addition to holding analyst roles at Farallon Capital Management, Madison Dearborn Partners, and Lehman Brothers. | |
Jeremy Grant Board | Independent Director | Founder and Managing Partner, Harbor Ridge LP; Special Advisor, Irenic Capital Management LP; Board Member, Acosta Inc.; Observer, Arconic Corporation | Jeremy Grant has served as an independent director at TBPH since December 2023, leveraging his extensive experience in finance and investment management from roles at Harbor Ridge LP, Irenic Capital Management LP, Acosta Inc., and others. | |
Laurie Smaldone Alsup Board | Director | Senior Vice President of Regulatory Science at SSI-NDA; Board member at BlackBerry Limited; Board member at Arvinas, Inc. | Laurie Smaldone Alsup, M.D. has served as a director at Theravance Biopharma since February 2018, bringing extensive expertise in regulatory science and clinical development to the board. She has also taken on leadership roles outside TBPH, including her current position as Senior Vice President of Regulatory Science at SSI-NDA and board memberships at BlackBerry Limited and Arvinas, Inc.. | |
Anne O’Connor | The documents do not provide any information about Anne O’Connor’s background or role at TBPH. |
-
Given that YUPELRI's hospital volume accounts for only 10% of total brand volume, can you clarify why non-hospital sales dollars are not growing at the same rate as hospital sales, and what strategies are in place to drive non-hospital demand?
-
With the upcoming CYPRESS study readout for Ampreloxetine, can you elaborate on the specific challenges you foresee in achieving the primary endpoints, and how previous clinical data support your confidence in a positive outcome?
-
Despite emphasizing strict expense management, SG&A expenses are expected to increase in 2025; can you provide more details on the drivers behind this increase and how it aligns with your commitment to capital discipline?
-
Considering the potential $150 million in TRELEGY-related milestones, how are you mitigating the risks associated with relying on these milestones for your financial stability, especially in light of the recent accounting changes affecting recognition of these milestones?
-
Can you discuss any competitive pressures in the COPD market that might impact YUPELRI's future growth, and how you plan to sustain the strong hospital performance while also accelerating growth in the community setting?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Sunovion Pharmaceuticals Inc. | Voluntarily withdrew Lonhala Magnair (glycopyrrolate) from the US market due to limited utilization, leaving YUPELRI as the only approved nebulized LAMA. |
Launched ensifentrine, a first-in-class, selective inhaled dual inhibitor of PDE3 and PDE4, in the US in June 2024 as a maintenance treatment for adults with COPD. | |
Received US approval for Dupixent (dupilumab), an IL-4/IL-13 monoclonal antibody, for COPD maintenance treatment for patients with moderate-to-severe COPD who are uncontrolled with current SOC triple therapy and have evidence of Type 2 inflammation and frequent exacerbation history. | |
Lundbeck NA Ltd. | Markets Northera, the branded version of droxidopa, which became generic in 2021 and is currently the sole product approved for nOH patients. |
Competes in COPD treatment with Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate, dosed twice per day) and in asthma treatment with Symbicort, a LABA/ICS combination. | |
Chiesi Farmaceutici | Competes in COPD treatment in Europe with Trimbow (beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide, dosed twice per day). |
Competes in asthma treatment in Japan with Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate, dosed once daily). | |
Boehringer Ingelheim | Competes in COPD and asthma treatment with Spiriva, a LAMA used in open triple therapy. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Viatris | Collaboration established in 2015 for YUPELRI (revefenacin) in COPD | All | Accounted for 100% of total revenue in 2024 ($64.381 million ) and 2023 ($57.424 million ). Also represented 100% of receivables from collaborative arrangements in 2024 and 2023. |
Recent press releases and 8-K filings for TBPH.
- YUPELRI delivered strong US net sales of ~$58M (up 6% YoY) and TRELEGY reported global net sales of $854M (up 14% YoY) with secured milestone payments .
- Ended Q1 with robust liquidity of $131M in cash and no debt; GAAP net loss of $13.6M, non‐GAAP net loss of $8.6M, plus $15.4M revenue from the Viatris collaboration .
- Subgroup analyses showed ampreloxetine achieved clinically meaningful improvement in nOH symptoms for MSA patients after 16 weeks, with sustained benefits in symptom management and functional activities .
- The CYPRESS Phase III study for ampreloxetine is nearing enrollment completion, with top‐line data expected in about 6 months (final patient by late summer) .
- YUPELRI also saw hospital channel volumes increase by 48% (316K doses) .
- Theravance Biopharma announced new analyses of its Phase 3 program for ampreloxetine, an investigational once-daily norepinephrine reuptake inhibitor for symptomatic nOH, to be presented at the 77th Annual AAN Meeting in San Diego, CA (April 5-9, 2025).
- The analyses support a selective pharmacodynamic profile and include data from both initial Phase 3 studies and the ongoing confirmatory CYPRESS Study addressing nOH in MSA patients.